Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of December 28, 2025 [1] Core Insights - The report highlights the intensive policy support for brain-computer interface (BCI) technology development, particularly in the medical field, with several policies already implemented [2] - It emphasizes the significant market opportunity in radiation therapy equipment, particularly the ZAP-X system, which is expected to capture a substantial share of the growing market for non-invasive tumor radiation treatment [3] - The introduction of pathology fee reforms is seen as a breakthrough for the commercialization of AI applications in pathology, allowing for better integration of AI-assisted diagnostics into the pricing structure [5] - The report discusses the trend of Chinese innovative drugs entering international markets, which is expected to reduce domestic competition and provide new valuation anchors for these companies [6] - It also notes the promising developments in oral autoimmune drugs and small nucleic acid drugs, with several companies making significant progress in clinical trials [7][9] Summary by Sections 1. Policy Support for BCI Technology - In July 2025, a joint opinion was issued by multiple government departments to promote BCI industry innovation, with medical health being a core application area [2] - The National Medical Products Administration (NMPA) has prioritized the approval of implantable BCI medical devices, with expected registration certificates to be issued by Q1 2026 [2] 2. Radiation Therapy Equipment Market - The ZAP-X system is designed for precise radiation therapy for brain tumors, with a significant patient population in China, estimated at 1.5 million new cases of brain metastases annually [3] - The non-invasive tumor radiation treatment market is projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% [3] 3. AI in Pathology - The NMPA's new guidelines for pathology services include AI-assisted diagnostics as an expansion item, which will help streamline the commercialization of AI technologies in pathology [5] 4. Innovative Drug Exports - The report notes that partnerships between Chinese companies and international firms are increasing, providing funding and reducing competition in the domestic market [6] - The innovative drug index has risen by 38.11% since the beginning of 2025, outperforming the CSI 300 index [6] 5. Oral Autoimmune Drugs - Takeda's new oral TYK2 inhibitor has shown positive results in clinical trials for psoriasis, indicating a potential breakthrough in treatment options [7] - Several domestic companies are also advancing in the development of oral autoimmune drugs targeting various conditions [7] 6. Small Nucleic Acid Drugs - Yuyuan Pharmaceutical's YKYY032 injection has received clinical approval from both the FDA and NMPA, with multiple companies in China advancing in the small nucleic acid drug space [9] - The report highlights the reliability of domestic technology platforms as they progress through clinical trials [9] 7. Stock Recommendations - The report recommends specific companies based on the identified opportunities, including Meihua Medical for BCI technology, Baiyang Pharmaceutical for ZAP-X, and Yuyuan Pharmaceutical for small nucleic acid drugs [11]

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pathology business is entering a fast track with the National Healthcare Security Administration issuing guidelines for pricing projects in pathology services, focusing on biopsy sampling, sample processing, and digitalization of pathology data, which is expected to enhance the application of AI in the field [3][11]. - The influenza activity has peaked across the board, with reported cases in southern provinces at 9.7%, down from 11.2% the previous week, but higher than the same period in previous years [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 0.14% from December 15 to December 19, outperforming the Wind All A index (-0.15%) and the CSI 300 index (-0.28%). The rebound was weak, with segments like pharmaceutical distribution (5.59%), offline pharmacies (4.69%), and hospitals (4.15%) leading gains, while chemical preparations (-2.1%), vaccines (-0.87%), and medical R&D outsourcing (-0.87%) lagged [3][8]. - Notable stock performances included Huaren Health (55.9%), Luyuan Pharmaceutical (36.8%), and Shuyupingmin (35.7%) with significant gains, while *ST Changyao (-24%), Yipinhong (-23.7%), and Rejing Biology (-16.5%) faced substantial declines [3][11]. Industry News and Key Company Announcements - The National Healthcare Security Administration's guidelines for pathology services are expected to drive high-quality development in the sector and create new scenarios for AI-assisted technology applications [11]. - Significant collaborations and approvals were reported, including Shanghai Jinmante's partnership with Jiangsu Kangning Jerey for a breakthrough therapy designation from the FDA for JSKN003, and Novo Nordisk's submission of a marketing application for CagriSema, which showed a weight loss of 22.7% over 68 weeks in clinical trials [12][13]. - Fosun Pharma's subsidiary received FDA approval to initiate a Phase I clinical trial for HLX18, a biosimilar to Nivolumab, targeting various cancers [13][14].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is opening up long-term value for companies, with significant collaborations occurring since September 2025. The innovative drug index has decreased by 11.34% from September 1 to December 19, underperforming the CSI 300 index by 12.93 percentage points. However, the index has increased by 38.65% since the beginning of the year, outperforming the CSI 300 index by 20.76 percentage points [2] - The report emphasizes the importance of oral immunomodulatory drugs, highlighting the positive results from Takeda's TYK2 inhibitor, zasocitinib, in treating moderate to severe plaque psoriasis. This drug is expected to provide significant benefits to patients and is part of a broader trend of domestic companies developing oral immunomodulatory drugs [3] - The report notes the progress of domestic small nucleic acid drugs, with YKYY032 receiving clinical approval from both the FDA and NMPA. The report anticipates an increase in clinical approvals for small nucleic acid drugs by 2026, as more companies enter this field [5] - The report tracks the flu season, indicating a peak in flu cases and a corresponding increase in the use of new flu medications, which are expected to see significant sales growth due to improved treatment protocols and online sales [7] - The report highlights a recovery in the financing of domestic innovative drugs, with a total financing amount of $5.51 billion in the first three quarters of 2025, a 67.6% increase year-on-year. The report also notes a significant increase in orders for CXO companies, indicating a positive trend in the industry [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.14 percentage points in the last week, ranking 22nd among 31 sectors [20] - Over the past month, the pharmaceutical industry underperformed the CSI 300 index by 2.06 percentage points, ranking 19th [24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has decreased by 2.50% over the past month, underperforming the CSI 300 index by 2.06 percentage points [40] - The current PE (TTM) for the pharmaceutical industry index is 37.07, above the five-year historical average of 31.16 [44] 3. Recent Research Achievements - The report includes various deep-dive studies on the pharmaceutical industry, focusing on topics such as the growth of oral drugs and the stability of blood products [48] 4. Recent Industry Policies and News - Recent policies from the National Healthcare Security Administration aim to improve the quality and efficiency of medical insurance fund settlements, which could positively impact the pharmaceutical sector [50] - Significant news includes the approval of new drugs by various companies, indicating ongoing innovation and development within the industry [51][52]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) has received approval from the National Medical Products Administration (NMPA) for its subsidiary's clinical trial of YKYY032 injection for the treatment of lipoprotein(a) hyperlipidemia, as well as a "Study May Proceed" letter from the FDA for the same purpose [1][1]. Group 1 - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have obtained the NMPA's approval for the clinical trial of YKYY032 injection [1]. - The FDA has granted a "Study May Proceed" letter for YKYY032 injection, indicating that clinical trials can commence in the United States [1]. - YKYY032 injection is a chemically synthesized double-stranded siRNA drug that targets the LPA gene to block the production of lipoprotein(a) [Lp(a)] through RNA interference mechanisms [1]. Group 2 - Preclinical studies have demonstrated significant pharmacological activity of YKYY032, effectively reducing LPAmRNA and Lp(a) protein levels in various animal models [1]. - In non-human primate models, YKYY032 has shown a reduction in LDL-C and ApoB levels, indicating a good and lasting lipid-lowering effect [1]. - Toxicity studies from repeated dosing have confirmed the drug's good safety and tolerability profile [1].

Core Viewpoint - YKYY032 injection has received approval for clinical trials in China and the United States for the treatment of hyperlipoproteinemia(a) [1] Group 1: Regulatory Approvals - The company’s subsidiary, Beijing YKYY Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have obtained the clinical trial approval notice from the National Medical Products Administration for YKYY032 injection [1] - The company has also received a "Study May Proceed Letter" from the U.S. Food and Drug Administration, allowing clinical trials for YKYY032 injection [1] Group 2: Drug Mechanism and Efficacy - YKYY032 injection is a chemically synthesized double-stranded siRNA drug that utilizes RNA interference to specifically silence the mRNA of the LPA gene, thereby blocking the generation of lipoprotein(a) [Lp(a)] [1] - Preclinical studies have shown that the drug exhibits significant pharmacological activity both in vitro and in vivo, effectively reducing LPA mRNA and Lp(a) protein levels in various animal models [1] - In non-human primates, the drug has also been associated with reductions in LDL-C and ApoB levels, demonstrating a good and lasting lipid-lowering effect [1] Group 3: Safety and Tolerability - Repeated dosing toxicity studies have confirmed that YKYY032 injection possesses good safety and tolerability [1]

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd., have recently received approval from the National Medical Products Administration for the clinical trial of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - Yuyuan Kechuang has also received a notification from the U.S. Food and Drug Administration (FDA) granting permission to conduct clinical trials for YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1]

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for the clinical trial of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - The approval from the National Medical Products Administration includes the issuance of a "Drug Clinical Trial Approval Notice" for YKYY032 injection [1] - Yuyuan Kechuang has also received a letter of consent from the U.S. Food and Drug Administration to conduct clinical trials for YKYY032 injection for the same indication [1]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) announced that its subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received NMPA approval for clinical trials of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - The YKYY032 injection is a chemically synthesized double-stranded siRNA drug that utilizes RNA interference to specifically silence the mRNA of the LPA gene, thereby blocking the production of lipoprotein(a) [Lp(a)] from the source [1] - The approval from both NMPA and FDA for the clinical trial application of YKYY032 marks a significant milestone in the company's new drug development [1] - The drug development process is lengthy, involves multiple stages, and carries high risks, indicating that it will not have a significant impact on the company's short-term performance [1]